As of May 2012 websites are required by law to gain your consent before applying cookies. We use cookies to improve your browsing experience. Parts of the website may not work as expected without them. By closing this message, you are consenting to our use of cookies. Close Learn more


Rheumatoid Arthritis Package


> Download your free sample > Contact us to find out more



This comprehensive coverage provides up-to-date opinions and forecasts based on extensive secondary research backed by a survey of 136 high prescribing rheumatologists and detailed discussions with KOLs.  Learn how the disease is currently treated, the unmet needs and how new market entrants (branded and generics/biosimilars) will affect the market in the future.

The Datamonitor Healthcare difference

What this package includes

Total number of physicians interviewed

US Japan France Germany Italy Spain UK
Rheumatologists 32 21 16 16 17 17 17


Coverage summary

Reports included in package
  • Epidemiology
  • Marketed drugs profiles
  • Pipeline drugs profiles
  • Treatment (physician insights)
  • Patient-based drug forecasts
Countries evaluated US, Japan, France, Germany, Italy, Spain, UK
Patient-based drug forecast period 2012–21
Patient subpopulations forecasted
  • Line of therapy
Drugs profiled
  • Actemra/RoActemra
  • Cimzia
  • Enbrel
  • Humira
  • Orencia
  • Remicade
  • Rituxan
  • Simponi
  • Xeljanz
  • FosD
  • baricitinib
  • sarilumab
  • secukinumab
  • sirukumab
  • tabalumab



Key Findings

Interest in the rheumatoid arthritis remains high, despite it being already crowded with nine biologics and numerous generics for first-line therapy. Key opinion leaders stress that physicians will struggle to distinguish between the various therapies. To stand out, companies should pursue markers that indicate likely responders, which would be welcomed by physicians and would allow them to offer a tailored treatment approach. Going forward, Datamonitor Healthcare believes that pursuing head-to-head studies of new drugs and marketed biologics will become a necessity in Phase III programs. Physicians will require this to know where new drugs may fit into the algorithm. Meanwhile, established brands will need to rethink marketing strategies to maintain uptake in the future.

> Download your free sample > Contact us to find out more

Datamonitor Healthcare is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726